This is a routine resale registration for existing shareholders from a prior private placement, not a new equity raise. The selling pressure is limited to 2.5% of shares outstanding, and the company's strong Q1 results and $50.3M cash position suggest no near-term capital need. Monitor for any subsequent prospectus supplement that could indicate a new primary offering.
Price Chart
Executive Summary
Profound Medical filed an S-3 registration statement to register 921,428 common shares for resale by selling shareholders who acquired them in a December 2025 private placement at $7.00/share. The company is not selling any shares or receiving proceeds from this filing. This is a routine resale registration for existing shareholders, not a new capital raise, and follows strong Q1 2026 results with 104% revenue growth and improved operating performance.
Key Financial Metrics
Key Facts
- S-3 registers 921,428 common shares for resale by selling shareholders from a December 2025 private placement
- Shares were issued at $7.00 per share for aggregate gross proceeds of approximately $6.45 million
- Company will not receive any proceeds from the resale of shares under this prospectus
- Filing follows Q1 2026 earnings (May 7) showing 104% revenue growth to $5.3M and net loss improvement of 34% to $0.19/share
- Company had $50.3M cash as of March 31, 2026, with $59.4M in shareholders' equity
- Selling shareholders include Fidelity True North Fund (300,000 shares) and funds associated with Timelo Investment Management (571,428 shares)
- Registration covers approximately 2.5% of outstanding shares (36.3M shares outstanding as of May 7, 2026)
Financial Impact
No new capital raised; potential overhang of 921,428 shares (2.5% of outstanding) at ~$7.25/share market price, representing ~$6.7M in potential selling pressure
Risk Factors
- Potential overhang from selling shareholders could create near-term downward pressure on stock price
- Fidelity True North Fund and Timelo funds are significant holders; their selling could signal reduced conviction
- Company remains pre-profitable with accumulated deficit of $294.8M and may need additional capital in the future
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001104659-26-059487 |
| Document: tm2614107d1_ex-filingfees.htm | 0001104659-26-059487 |
| Document: tm2614107d1_ex5-1.htm | 0001104659-26-059487 |
| Document: tm2614107d1_ex23-1.htm | 0001104659-26-059487 |
| Document: 0001104659-26-059487-index-headers.html | 0001104659-26-059487 |
| Document: 0001104659-26-059487-index.html | 0001104659-26-059487 |
| Document: 0001104659-26-059487.txt | 0001104659-26-059487 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 8-K | $6.89 $5.81 | ▼ −15.67% | ▼ −14.47% | $5.85 (−15.09%) |
Sep 3, 2026 29d ago | 8-K | $6.80 $5.97 | ▼ −12.21% | ▼ −11.06% | $5.85 (−13.97%) |
Aug 17, 2026 6w ago | 8-K | $6.55 $6.80 | ▲ +3.82% | ▲ +5.01% | $5.85 (−10.69%) |
Aug 17, 2026 6w ago | 8-K | $6.55 $6.80 | ▲ +3.82% | ▲ +5.01% | $5.85 (−10.69%) |
Jul 24, 2026 10w ago | 8-K | $7.26 $7.25 | ▼ −0.14% | ▼ −0.51% | $5.85 (−19.42%) |
Jul 15, 2026 11w ago | 8-K | $6.96 $6.99 | ▲ +0.43% | ▲ +1.41% | $5.85 (−15.95%) |
May 14, 2026 20w ago | 8-K | $6.97 $6.83 | ▼ −2.01% | ▼ −2.97% | $5.85 (−16.07%) |
May 12, 2026 20w ago | S-3 | $7.10 $6.73 | ▼ −5.21% | ▼ −4.05% | $5.85 (−17.61%) |
Apr 16, 2026 24w ago | 8-K | $6.62 $6.75 | ▲ +1.96% | ▲ +0.98% | $5.85 (−11.63%) |
Apr 14, 2026 24w ago | 8-K | $6.26 $6.84 | ▲ +9.27% | ▲ +7.87% | $5.85 (−6.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access